Answers are grounded in this paper and cite their sources.
Tumor subclonal architecture shapes cancer evolution, yet subclonal reconstruction from bulk sequencing remains difficult to scale due to computational cost and model complexity. We present CliPP, a penalized-likelihood framework that jointly estimates cellular prevalence with pairwise fusion penalties, automatically identifying subclones without requiring extensive priors. Across simulations and 2,778 whole-genome tumors with external consensus reconstructions, CliPP achieves consistently good performances when compared to state-of-the-art approaches while providing substantial runtime reductions. Applied to 7,000+ tumors across >30 cancer types, CliPP quantifies pervasive subclonality and delineates cohort-level subclone landscapes. CliPP enables fast, reproducible large-scale subclonal analysis and is freely available to the community through GitHub and a shiny app.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2021) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: